Who is the CEO of Aribiolab?

According to the DART company overview, Aribiolab's representative director is 정재준 (name as registered in Korean). The company was founded on 2000-06-09.

Where is Aribiolab listed?

Aribiolab trades on the Korea Exchange KOSDAQ market under the ticker 261780. Its fiscal year ends in December.

Does Aribiolab pay a dividend?

Aribiolab did not pay a cash dividend for fiscal 2025, according to its annual report.

Does Aribiolab have any recent filing signals?

Signals detected automatically from DART filings and quarterly results: Dilution risk (rights offering or CB/BW/EB issue decided in the past 90 days); 4 quarters of losses (operating loss in each of the last four quarters); Control change (change of largest shareholder, or a contract that would cause one (90 days)); Private placement (third-party allotment rights offering decided in the past 90 days). 1 more signal is shown on the page. These are factual flags, not investment advice.

Which companies are in the same industry as Aribiolab?

Under the Korean Standard Industrial Classification recorded on DART, Aribiolab is grouped with 53 other listed companies in medical & pharmaceutical r&d. The most covered in Korean news over the past 30 days are Alteogen, Qurient and SillaJen.

Aribiolab KRX:261780KOSDAQ

차백신연구소 · Korean news coverage and regulatory filings, organized.

한국어

Articles, 24h0

Articles, 7 days1

DART filings, 7 days0

Articles tracked18since Sep 11

In Q2 2026, Aribiolab reported revenue of ₩0m, down 100.0% year on year, and an operating loss of ₩2.5bn. Aribiolab (차백신연구소) appeared in 1 Korean news article and 0 DART filings over the past seven days. Coverage peaked on Oct 19 with 1 article. It was most often mentioned alongside HYBE.

Filing signals Control change Private placement Dilution risk 4 quarters of losses Share pledge Screener

Aribiolab quarterly results separate, KRW

Quarter	Revenue	YoY	Operating profit	Net income
Q2 2026	₩0m	-100.0%	−₩2.5bn	−₩2.7bn
Q1 2026	₩173m	–	−₩1.7bn	−₩2.1bn
Q4 2025 derived	₩0m	–	−₩5.4bn	−₩5.9bn
Q3 2025	–	–	−₩3.4bn	−₩3.8bn
Q2 2025	₩159m	–	−₩3.1bn	−₩3.8bn
Q1 2025	–	–	−₩2.4bn	−₩2.6bn
Q4 2024 derived	₩0m	–	−₩2.2bn	−₩4.1bn
Q3 2024	–	–	−₩1.9bn	−₩1.9bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Aribiolab top stories 2 weeks, by number of outlets

1
아리바이오랩, 대상포진 백신 2상 환자 모집 종료
1 outlets · 1 articlesFirst report Oct 29 09:38 메디코파마
2
아리바이오랩, 선천면역 깨우는 면역증강 플랫폼… 대상포진·치매 등으로 임상 확대
1 outlets · 1 articlesFirst report Oct 23 08:08 한국경제
3
[MK 골든크로스 돌파종목 : 하이브(352820) & 아리바이오랩(261780)]
1 outlets · 1 articlesFirst report Oct 19 09:25 매일경제HYBE

Latest Aribiolab news Korean headlines

Oct 2909:38

아리바이오랩, 대상포진 백신 2상 환자 모집 종료
메디코파마
Oct 2308:08

아리바이오랩, 선천면역 깨우는 면역증강 플랫폼… 대상포진·치매 등으로 임상 확대
한국경제
Oct 1909:25

[MK 골든크로스 돌파종목 : 하이브(352820) & 아리바이오랩(261780)]
매일경제HYBE
Sep 1818:03

아리바이오LAB, 180억원 규모 유상증자 실시
매일경제
Sep 1808:52
아리바이오, 150억 투자해 아리바이오랩 최대주주로
알파경제ARIBIO Holdings
1 more on this story · 1 outlets
- 아리바이오, 150억 투자해 아리바이오랩 최대주주로메디컬투데이 · Sep 18 08:52
Sep 1706:50

아리바이오랩 180억 유증…아리바이오, 최대 지분주주로 부상
메디코파마ARIBIO Holdings
Sep 1616:10
아리바이오랩, 180억 규모 유증…아리바이오 최대주주로
이데일리ARIBIO Holdings
2 more on this story · 2 outlets
- 아리바이오랩, 180억 규모 유증…아리바이오 최대주주로이데일리 · Sep 16 16:08
- 아리바이오랩, 180억 규모 유증…아리바이오 최대주주로이데일리증권 · Sep 16 16:08
Sep 1615:26

아리바이오랩, 180억 제3자배정 유상증자
연합뉴스경제
Sep 1612:20

"신물질 플랫폼 경쟁력 확보"…인바이오, 아리바이오랩에 30억 전략적 투자
더페어뉴스Enbio
Sep 1610:07
인바이오, 아리바이오랩에 30억원 투자…바이오 신물질 사업 확대
메디컬투데이Enbio
4 more on this story · 4 outlets
- 인바이오, 아리바이오랩에 30억원 투자…바이오 신물질 사업 확대알파경제 · Sep 16 10:07
- 인바이오, 아리바이오랩에 30억원 투자…바이오 신물질 R&D로 사업 확장더바이오 · Sep 16 10:28
- 인바이오, 아리바이오랩에 30억원 투자뉴스핌 · Sep 16 10:44
- 인바이오, 아리바이오랩에 30억 전략적 투자…신물질 사업 확대이데일리 · Sep 16 11:25
Sep 1417:54

아리바이오LAB, 30억 원 규모 전환사채 발행
매일경제

Articles per day 2 weeks

119

123

129

Company profile

CEO: 정재준
Industry: Medical & pharmaceutical R&D
Founded: 2000-06-09
Fiscal year-end: December
Head office: 경기도 성남시
Website: chavaccine.com
Quotes & chart: Naver Securities (Korean)

From the DART company overview.

Major shareholders latest 5%+ report per holder

Korea 5% stake disclosures

아리바이오홀딩스20.69%
차바이오텍5.70%

Each holder's most recent 5% ownership report on DART; names as filed in Korean.

Same industry Medical & pharmaceutical R&D

All in industry

Company	Latest quarter op. profit	Articles 30d
Alteogen	₩34.2bn	223
Qurient	−₩12.8bn	74
SillaJen	−₩6.2bn	51
Rznomics	−₩6.9bn	47
LigaChem Biosciences	−₩72.0bn	43
OliX Pharmaceuticals	−₩14.0bn	36
D&D Pharmatech	−₩9.9bn	34
GI Innovation	−₩14.4bn	33

Compare Aribiolab side by side with these companies

Aribiolab DART filings

Oct 1617:20

Other 주요사항보고서(자기전환사채매도결정)
Other
Oct 1615:58

Other 증권발행결과(자율공시)
Other
Oct 615:20

Other 투자판단관련주요경영사항 (경영지배인 사임)
Other
Sep 2915:14

Other 주권관련사채권의취득결정
Other
Sep 2817:05

Convertible bond [기재정정]주요사항보고서(전환사채권발행결정)
Capital & M&A
Sep 2216:17

Convertible bond [기재정정]주요사항보고서(전환사채권발행결정)
Capital & M&A
Sep 2216:12

Other 증권발행결과(자율공시)
Other
Sep 1617:24

Rights offering [기재정정]주요사항보고서(유상증자결정)
Capital & M&A
Sep 1616:03

5% ownership report 주식등의대량보유상황보고서(일반)
Ownership reports
Sep 1615:22

Rights offering 주요사항보고서(유상증자결정)
Capital & M&A
Sep 1416:37

Convertible bond 주요사항보고서(전환사채권발행결정)
Capital & M&A
Sep 917:29

Convertible bond 주요사항보고서(전환사채권발행결정)
Capital & M&A

Mentioned alongside 2 weeks

1 HYBEKOSPI 1

Aribiolab FAQ

Who is the CEO of Aribiolab?: According to the DART company overview, Aribiolab's representative director is 정재준 (name as registered in Korean). The company was founded on 2000-06-09.
Where is Aribiolab listed?: Aribiolab trades on the Korea Exchange KOSDAQ market under the ticker 261780. Its fiscal year ends in December.
What were Aribiolab's latest quarterly results?: In Q2 2026, Aribiolab reported revenue of ₩0m, down 100.0% year on year, and an operating loss of ₩2.5bn. Figures come from reports filed on DART.
Does Aribiolab pay a dividend?: Aribiolab did not pay a cash dividend for fiscal 2025, according to its annual report.
Does Aribiolab have any recent filing signals?: Signals detected automatically from DART filings and quarterly results: Dilution risk (rights offering or CB/BW/EB issue decided in the past 90 days); 4 quarters of losses (operating loss in each of the last four quarters); Control change (change of largest shareholder, or a contract that would cause one (90 days)); Private placement (third-party allotment rights offering decided in the past 90 days). 1 more signal is shown on the page. These are factual flags, not investment advice.
Which companies are in the same industry as Aribiolab?: Under the Korean Standard Industrial Classification recorded on DART, Aribiolab is grouped with 53 other listed companies in medical & pharmaceutical r&d. The most covered in Korean news over the past 30 days are Alteogen, Qurient and SillaJen.